Evidence map›Paper›PMID 40954219›Full record

ArticleScientific reports2025

Genotype distribution and molecular characterization of HPV in the Peruvian amazon: insights into prevalence, lineage diversity, and viral integration.

Lesly Solis-Ponce, Milan Stosic, Greisi Curicó, Susan Espetia, Heidy Sanchez-Grandez, Sadaf Sakina Hassan, Jorge Basiletti, Kristiane Søreng, Maribel Acuña-Barrios, Lilian Huarca-Balbin and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lesly Solis-Ponce *Peruvian HPV National Reference Laboratory. National Reference Laboratory for Sexually Transmitted Viruses, National Institute of Health, Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Milan Stosic *Norwegian HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, 1478, Lørenskog, Norway.
Greisi CuricóInfectious and Tropical Diseases Research Laboratory, Loreto Regional Hospital, Avenida 28 de Julio S/N , 16004, Loreto, Maynas, Peru.
Susan EspetiaPeruvian HPV National Reference Laboratory. National Reference Laboratory for Sexually Transmitted Viruses, National Institute of Health, Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Heidy Sanchez-GrandezInfectious and Tropical Diseases Research Laboratory, Loreto Regional Hospital, Avenida 28 de Julio S/N , 16004, Loreto, Maynas, Peru.
Sadaf Sakina HassanInternational HPV Reference Center, Center for Cervical Cancer Elimination, F56, Karolinska University Hospital Huddinge, Karolinska Institutet, 141 86, Huddinge, Sweden.
Jorge BasilettiArgentinian HPV Reference Laboratory, National Institute of Infectious Diseases-ANLIS "Dr. Malbrán", C1282AFF, Buenos Aires, Argentina.
Kristiane SørengNorwegian HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, 1478, Lørenskog, Norway.
Maribel Acuña-BarriosPeruvian HPV National Reference Laboratory. National Reference Laboratory for Sexually Transmitted Viruses, National Institute of Health, Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Lilian Huarca-BalbinCenter for Evaluation of Health Technologies, National Institute of Health (Peru), Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Mariela Yaya-RíosPeruvian HPV National Reference Laboratory. National Reference Laboratory for Sexually Transmitted Viruses, National Institute of Health, Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Giovanny Vilcarino-ZevallosPeruvian HPV National Reference Laboratory. National Reference Laboratory for Sexually Transmitted Viruses, National Institute of Health, Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Renzo LopezLoreto Regional Hospital, Avenida 28 de Julio S/N, 16004, Loreto, Maynas, Peru.
Andrea MatosDirección de Prevención y Control del Cáncer, Ministerio de Salud, Av. Salaverry 801, 15072, Jesús María, Lima, Peru.
Cesar Ramal-AsayagInfectious and Tropical Diseases Research Laboratory, Loreto Regional Hospital, Avenida 28 de Julio S/N , 16004, Loreto, Maynas, Peru.
George ObregonPeruvian HPV National Reference Laboratory. National Reference Laboratory for Sexually Transmitted Viruses, National Institute of Health, Avenida Defensores del Morro 2268, 15067, Chorrillos, Lima, Peru.
Laila Sara Arroyo MührInternational HPV Reference Center, Center for Cervical Cancer Elimination, F56, Karolinska University Hospital Huddinge, Karolinska Institutet, 141 86, Huddinge, Sweden. sara.arroyo.muhr@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer remains a leading cause of cancer-related mortality among women in Peru, with the highest death rates reported in the Amazon region. Despite this burden, molecular data on human papillomavirus (HPV) in this area are limited. This study aimed to assess HPV genotype distribution and molecular characteristics in women undergoing cervical screening in the Peruvian Amazon. Between May and November 2024, cervical samples were collected from 503 women aged 25-55, along with an additional subset of 35 women with histologically confirmed CIN2 + lesions. HPV genotyping was performed using the Allplex™ HPV28 assay, and single infections with HPV16 or HPV52 were further analyzed by TaME-seq to determine lineage, intrahost variability, and integration. HPV prevalence was 51.7% (278/538), with high rates of multiple infections (44.2%) and low vaccination coverage (7.8%). Oncogenic HPV types were detected in 35.7% (192/538) of participants, with HPV 16 and HPV 52 being the most prevalent. Sublineage analysis revealed predominance of A1 variants, while viral integration was detected in nine cases, three associated with CIN2 + lesions. Integration sites occurred mainly in E1/E2 for HPV16 and L1/L2 for HPV52. These findings highlight the urgent need to expand vaccination and implement molecular screening strategies in the Peruvian Amazon.

Indexed as

PapillomaviridaePapillomavirus InfectionsUterine Cervical NeoplasmsVirus IntegrationAdultFemaleGenetic VariationGenotypeHuman papillomavirus 16HumansMiddle AgedPeruPrevalenceCervical cancerHuman papillomavirusIntegrationPeruvian amazonSublineagesTaME-seq

Identifiers

PMID40954219
PMCPMC12436591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.